

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6606)**

**POSITIVE PROFIT ALERT**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

The Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary review of the Group’s unaudited management accounts for the year ended December 31, 2021, the total revenue of the Group for the year ended December 31, 2021 is expected to be within the range of RMB205.2 million to RMB217.2 million, representing an increase in the range of 190.8% to 207.8% from approximately RMB70.6 million for the year ended December 31, 2020. The gross profit of the Group for the year ended December 31, 2021 is expected to be within the range of RMB147.0 million to RMB158.0 million, representing an increase in the range of 294.6% to 324.2% from approximately RMB37.2 million for the year ended December 31, 2020. The increase in total revenue and gross profit was mainly due to the increased revenue and the gross profit of our products, namely, ColoClear and Pupu Tube, which has led to the substantial increase in our total revenue. In particular,

- (i) the revenue from sales of ColoClear for the year ended December 31, 2021 is expected to be within the range of RMB95.0 million to RMB99.0 million, representing an increase in the range of 152.9% to 163.5% from approximately RMB37.6 million for the year ended December 31, 2020. The gross profit from sales of ColoClear for the year ended December 31, 2021 is expected to be within the range of RMB70.0 million to RMB76.0 million, representing an increase in the range of 178.7% to 202.5% from approximately RMB25.1 million for the year ended December 31, 2020. The increase in the revenue and gross profit from sales of ColoClear is due to (a) the increase in volume of ColoClear sold and recognized as revenue; and (b) the increase in revenue per test due to higher proportion of revenue generated from channels with more favorable revenue per test (such as hospital and direct-to-consumer channels); and

- (ii) the revenue from sales of Pupu Tube for the year ended December 31, 2021 is expected to be within the range of RMB110.0 million to RMB118.0 million, representing an increase in the range of 245.5% to 270.6% from approximately RMB31.8 million for the year ended December 31, 2020. The gross profit from sales of Pupu Tube for the year ended December 31, 2021 is expected to be within the range of RMB78.0 million to RMB84.0 million, representing an increase in the range of 435.2% to 476.4% from approximately RMB14.6 million for the year ended December 31, 2020. The increase in the revenue and gross profit from sales of Pupu Tube is due to (a) the increase in volume of Pupu Tube sold and recognized as revenue; and (b) higher revenue per product as a result of higher ex-factory price within each channel and lower proportion of revenue from channels with lower ex-factory price (such as government-sponsored community screening programs).

The gross profit margin of the Company for the year ended December 31, 2021 is expected to be within the range of 67.7% to 77.0%, representing a trend of increase compared to approximately 52.8% for the year ended December 31, 2020. The increase in our overall gross profit margin was mainly due to the increased gross profit margin of ColoClear and Pupu Tube. In particular,

- (i) the gross profit margin for ColoClear for the year ended December 31, 2021 is expected to be within the range of 70.7% to 80.0%, representing a significant increase compared to approximately 66.9% for the year ended December 31, 2020 due to the increase in revenue per test due to higher proportion of revenue generated from channels with more favorable revenue per test (such as hospital and direct-to-consumer channels); and
- (ii) the gross profit margin for Pupu Tube for the year ended December 31, 2021 is expected to be within the range of 66.1% to 76.4%, representing a significant increase compared to approximately 45.8% for the year ended December 31, 2020 due to higher revenue per test (both on blended basis and for each individual channel) and lower manufacturing cost per unit.

The Company is still in the process of finalizing the financial results of the Group for the year ended December 31, 2021. The operating statistics disclosed above are unaudited and based on the preliminary internal information of the Group, which may be subject to change and may differ from the figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such operating information. Such information has not been audited or reviewed by the auditors of the Company or the audit committee of the board of directors (the “**Board**”) of the Company. They shall not be taken as a measure or indication of the Group’s current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Group’s audited or unaudited consolidated financial statements. As such, the above statistics are provided for investors’ reference only.

**Shareholders of the Company and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek professional advice from professional or financial advisers.**

By order of the Board  
**New Horizon Health Limited**  
**Dr. Yiyou CHEN**  
*Chairman*

Hong Kong, January 14, 2022

*As at the date of this announcement, the Board of the Company comprises Dr. Yiyou CHEN as Chairman and executive Director, Mr. Yeqing ZHU as executive Director, Mr. Naxin YAO and Ms. Nisa Bernice Wing-Yu LEUNG as non-executive Directors, and Mr. Danke YU, Prof. Hong WU and Dr. Kwok Tung LI, Donald as independent non-executive Directors.*